OMERACTOutcome Measures in Rheumatoid Arthritis Clinical Trials
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
In RA and SpA, three PROs have been included within the American College of Rheumatology core set of outcome measures recommended for use in randomized clinical trials [63] as a part of the OMERACT PsA Core Domain Set [64] and the International Classification of Functioning, Disability and Health Core Set for AS [65] and clinical care including global ratings of disease activity or health, pain, and physical function; more recently, fatigue and emotional distress also has been recommended for inclusion [25, 63, 66, 67].
Idzerda, "OMERACT: an international initiative to improve outcome measurement in rheumatology," Trials, vol.
[8] "OMERACT conference on outcome measures in rheumatoid arthritis clinical trials," Journal of Rheumatology, vol.
Patient-reported pain is central to OMERACT rheumatology core measurement sets.
Actualmente, el mejor sistema de puntaje validado es el desarrollado por la Omeract (International Consensus Conference on Outcome Measures in Rheumatology) (61, 62) que ha demostrado buena correlacion entre los puntajes y los volumenes de sinovitis y erosiones.
A secondary outcome measure was response according to criteria established by the Outcome Measures in Rheumatology Clinical Trials (OMERACT) and Osteoarthritis Research Society International (OARSI) task force, which includes changes in pain, function, and patient's global assessment.
Compared with naproxen (1 g), no difference was seen in efficacy in the OMERACT outcomes (Outcome Measures for Rheumatoid Arthritis Clinical Trials), but all combined GI adverse events (perforation, ulcer, obstruction, bleeding, and all episodes of GI bleeding) were significantly reduced at 9 months (NNH=20).
However, the most validated scoring system, Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis Magnetic Resonance Image Score, showed good overall intrareader agreement in the hand and foot and inflammatory feature scores responsive to change (67-69).
The definitions of the applied MRI RA pathologies were in accordance with the Outcome Measures in Rheumatology Clinical Trials (OMERACT) recommendations (13).
However, several other indices have been especially developed for PsA, and the Group of Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and Outcome Measures in Rheumatology (OMERACT) have been working on developing conclusive indices for PsA.